


PC19103B  
Information Disclosure Statement For Appln. No. To be assigned  
Div. of 10,460,010

Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail EL 969716585 US in an envelope  
addressed to Mail Stop: Patent Applications,  
Commissioner for Patents, PO Box 1450, Alexandria,  
VA 22313-1450, on this 9th day of March 2004.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
COLLINS, ET AL

Group Art Unit: 1625

Serial No.: To be assigned  
(DIV of 10/450,010)

Examiner: Charanjit Aulakh

Confirmation No.: TBA

Filed: Concurrently herewith

For: BENZOFUSED HETEROARYL AMIDE  
DERIVATIVES OF THIENOPYRIDINES  
USEFUL AS THERAPEUTIC AGENTS,  
PHARMACEUTICAL COMPOSITIONS  
INCLUDING THE SAME, AND METHODS  
FOR THEIR USE

Mail Stop: Patent Applications  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a

that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☒ This application is a continuation, divisional or continuation-in-part of Serial No. 10/460,010. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: March 9, 2004

  
\_\_\_\_\_  
Stephen D. Prodruk  
Attorney For Applicant  
Registration No. 43,020

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use as many sheets as necessary)

## **Complete if Known**

Application Number	to be assigned
Filing Date	March 9, 2004
First Named Inventor	Michael Collins et al.
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	PC19103B

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	A	5,587,458	12-24-1996	C. Richter King et al.	
	B	5,747,498	05-05-1998	Rodney Caughren Schnur	
	C	5,792,783	08-11-1998	Peng Cho Tang et al.	
	D	5,834,504	11-10-1998	Peng Cho Tang et al.	
	E	5,861,510	01-19-1999	Anthony Piscopio et al.	
	F	5,863,949	01-26-1999	Ralph P. Robinson et al.	
	G	5,877,305	03-02-1999	James S. Huston et al.	
	H	5,883,113	03-16-1999	Peng Cho Tang et al.	
	I	5,886,020	03-23-1999	Peng Cho Tang et al.	
	J	6,071,935	06-06-2000	Joseph P. Lyssikatos	
	K	6,502,129	12-31-2002	Daniel B. Stewart et al.	
	L	6,492,383	12-2002	Munchhof et al.	
	M	6,225,318	05-01-2001		
	N	6,492,383	12-10-202		

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AL	WO 90/05719	05-31-1990	British Bio-Technology Limited		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	to be assigned
Filing Date	March 9, 2004
First Named Inventor	Michael Collins et al.
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	PC19103B

AM	EP-0606,046	12-21-1993	Novartis AG		
AN	WO 95/19970	07-27-1995	Warner-Lambert Company		
AO	WO 95/21613	08-17-1995	Sugen, Inc. & Yssum		
AP	WO 95/23141	08-31-1995	Pfizer Inc.		
AQ	WO 96/14843	05-23-1996	Cor Therapeutics, Inc.		
AR	WO 96/27583	09-12-1996	Pfizer Inc.		
AS	WO 96/30347	10-03-1996	Pfizer Inc.		
AT	WO 96/33172	10-24-1996	Pfizer Inc.		
AU	WO 96/40142	12-19-1996	Pfizer Inc.		
AV	WO 97/13771	04-17-1997	Glaxo Group Limited		
AW	WO 97/13760	04-17-1997	Glaxo Group Limited		
AX	WO 97/22596	06-26-1997	Zeneca Limited		
AY	WO 97/32856	09-12-1997	Zeneca Limited		
AZ	WO 97/34876	09-25-1997	Zeneca Limited		
BA	WO 97/49688	12-31-1997	Pfizer, Inc.		
BB	WO 98/01113	01-15-1998	Seiken Chemical Co., LTD.		
BC	WO 98/02434	01-22-1998	Glaxo Group Limited		
BD	WO98/02438	01-22-1998	Glaxo Group Limited		
BE	WO 98/02437	01-22-1998	Glaxo Group Limited		
BF	WO 98/03516	01-29-1998	Pfizer Inc.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	to be assigned
Filing Date	March 9, 2004
First Named Inventor	Michael Collins et al.
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	PC19103B

	BG	WO 98/07697	02-26-1998	Pfizer Inc.		
	BH	WO 98/14451	04-09-1998	Novartis AG		
	BI	WO 98/23613	06-04-1998	Pfizer Inc.		
	BJ	WO 98/30566	07-16-1998	Pfizer Inc.		
	BK	WO 98/33768	08-06-1998	Pfizer Products Inc.		
	BL	WO 98/34918	08-13-1998	Pfizer Inc.		
	BM	WO 98/34915	08-13-1998	Pfizer Inc.		
	BN	WO 98/50356	11-12-1998	Sugen, Inc.		
	BO	WO 98/54093	12-03-1998	Merck & Co., Inc.		
	BP	WO 99/00797	01-07-1999	Aplus Flash Technology, Inc.		
	BQ	WO 99/10349	03-04-1999	Zeneca Limited		
	BR	WO 99/16755	04-08-1999	Merck & Co., Inc.		
	BS	WO 99/21845	05-06-1999	Agouron Pharmaceuticals Inc.		
	BT	WO 99/24440	05-20-1999	Pfizer Products Inc.		
	BU	WO 99/29667	06-17-1999	Pfizer Limited		
	BV	WO 99/35146	07-15-1999	Glaxo Group Limited		
	BW	WO 99/35132	07-15-1999	Glaxo Group Limited		
	BX	WO 99/52910	10-21-1999	Pfizer Products Inc.		
	BY	WO 99/52889	10-21-1999	Pfizer Products Inc.		
	BZ	WO 99/61422	12-02-1999	Sugen, Inc.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	to be assigned
Filing Date	March 9, 2004
First Named Inventor	Michael Collins et al.
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	PC19103B

	CA	WO 00/38665	07-06-2000	G. D. Searle & Co.		
	CB	EP- 0 780 386	10-02-2002	Hoffmann-La Roche AG		
	CC	EP- 0 931 788	11-16-2002	Pfizer Inc.		
	CC 2	WO 03/000,194	01-03-2003	Pfizer, Inc.		
	CC 3	WO 03/074,529	09-12-2003	Pfizer, Inc.		
	CC 4	WO 01/94353	12-13-2001	Pfizer Products Inc.		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CD	BAGSHAW, et. al., "Antibody-Directed Enzyme Therapy: A Review, " <i>Drug Development and Research</i> , 1995, 220-230, 34.	
	CE	BERTOLINI, et. al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>Journal of Medicinal Chemistry</i> , 1997, 2011-2016, 40.	
	CF	BODOR, et. al., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Res.</i> , 1984, 224-331, 13.	
	CG	BUNDGAARD, et. al., <i>Design and Application of Prodrugs, Drug Design and Development</i> , Harwood Academic Press, 1991.	
	CH	BUNDGAARD, et. al., <i>Design of Prodrugs</i> , Elsevier Press, 1985, New York.	
	CI	BUTTERY, et. al., "Preparation of 2,3-Disubstituted Indoles from Indole-3-carboxylic Acids and Amides by Deprotonation," <i>Journal of Chem. Soc. Perkin Trans</i> , 1993, 1425-1431.	
	CJ	PAGANO, Michele ed., <i>Cell Cycle: Materials and Methods</i> , 1995, Berlin, Germany.	
	CK	FLEISHER, et. al., , " Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 1996, 115-130, Vol. 19.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	to be assigned
Filing Date	March 9, 2004
First Named Inventor	Michael Collins et al.
Art Unit	1625
Examiner Name	Charanjit Aulakh
Attorney Docket Number	PC19103B

CL	GREEN, T., et. al., <u>Protecting Groups in Chemical Synthesis (3<sup>rd</sup> Edition)</u> , 1999, John Wiley & Sons, New York.	
CM	MOHAMMADI., et. al., "Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor Receptor 1 and Elucidation of Their Importance in Receptor Activation and Signal Transduction," <i>Molecular Cell and Biology</i> , 1996, 977-989, Vol. 16, No. 3.	
CN	PARAST, et. al., "Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR 2 TK), a Key Enzyme in Angiogenesis," <i>Biochemistry</i> , 1998, 16788-16801, 37.	
CO	ROBINSON, et. al., "Discovery of the Hemifumarate and (a-L-Alanylogy) methyl Ether as Prodrugs of an Antirheumatic Oxiindole: Prodrugs for the Enolic OH Group," <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1, 10-18.	
CP	SHAN, et. al., , "Prodrug Strategies Based on Intramolecular Cyclization Reactions," <i>Journal of Pharmaceutical Science</i> , 1997, 765-767, Vol. 86, No. 7.	
CQ	STILL, et. al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution," <i>Journal of Organic Chemistry</i> , 1978, 2923-2925, Vol 43, No. 14.	
CR	SWAIN, et. al., "Novel 5-HT <sub>3</sub> Antagonists: Indol-3-ylspiro(azabicycloalkane-3,5' (4'H)-oxazoles)," <i>Journal of Med. Chemistry</i> , 1992, 1019-1031, 35.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.